478 results
Page 3 of 24
6-K
EX-99.1
vv1tshrk
10 Nov 22
European Commission grants first approval worldwide of Beyfortus® (nirsevimab) for prevention of RSV disease in infants
2:00pm
6-K
EX-99.1
9mq0q1dm55nmeej2s0tq
28 Oct 22
Continued strong growth in Q3 with key regulatory milestones achieved
11:16am
6-K
EX-99.1
ii9yifu8an7q2rb6 92
17 Oct 22
68% of children on a higher dose of Dupixent achieved histological disease remission at week 16
1:35pm
6-K
EX-99.1
uyr opi5uhlc8qmr07
3 Oct 22
Dupixent® (dupilumab) approved by FDA as the first and only treatment indicated for prurigo nodularis
11:24am
6-K
EX-99.1
26c4pv83d2
22 Sep 22
CHMP recommends approval of Beyfortus® (nirsevimab) for prevention of RSV disease in infants
9:49am
6-K
EX-99.2
27av5w7hdy gv3v
12 Sep 22
Evolution of the Board of Directors
7:07am
6-K
EX-99.3
h9u1abf
12 Sep 22
Evolution of the Board of Directors
7:07am
6-K
EX-99.1
inioxgt xkqqoi6r
28 Jul 22
Strong execution in Q2 drives full-year 2022 guidance upgrade and delivers rich R&D news flow in Immunology and Rare Disease
10:12am
6-K
EX-99.2
wnn 28r49hycset
28 Jul 22
Condensed Half-year Consolidated Financial Statements
6:17am
6-K
EX-99.1
5pzjiyz q52
20 Jul 22
Dupixent® (dupilumab) Phase 3 trial shows positive results in children 1 to 11 years of age with eosinophilic esophagitis
12:38pm
6-K
EX-99.1
r16w19pz3 ifpf
13 Jun 22
FDA approves Dupixent® (dupilumab) as first biologic medicine for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis
2:56pm
6-K
EX-99.2
n0d f6aedq7j33c4qm0
31 May 22
Update on Cialis® Rx-to-OTC Switch Actual Use Trial
10:56am
6-K
EX-99.1
ifyg0cp8yir
25 May 22
FDA approves Dupixent® (dupilumab) as first treatment for adults and children aged 12 and older with eosinophilic esophagitis
1:53pm
6-K
EX-99.1
3rgbkp18kp 6szv
16 May 22
IFRS net sales reported
1:45pm
6-K
EX-99.1
3f7wst pw
28 Apr 22
Sanofi continues to deliver strong business EPS(1) growth driven by higher sales and improved margins in Q1
12:16pm
6-K
EX-99.1
4h2zl8v5 v183
19 Apr 22
Positive Phase 1/2 study results of rilzabrutinib in people with immune thrombocytopenia published in The New England Journal of Medicine
11:32am
6-K
EX-99.3
y3itpb3vwr dbp5
7 Apr 22
If approved, Dupixent would be the first medicine available in the U.S. indicated to treat eosinophilic esophagitis
3:13pm
6-K
EX-99.1
rfenl3ok7zb4ui9xtz
7 Apr 22
If approved, Dupixent would be the first medicine available in the U.S. indicated to treat eosinophilic esophagitis
3:13pm
6-K
EX-99.1
iexs3u6cz74nt0g
4 Apr 22
Distribution of Shares of Euroapi
11:21am
6-K
EX-99.3
hwfaaif
30 Mar 22
Late-breaking Phase 3 data at AAD 2022 show Dupixent® (dupilumab) significantly improved signs and symptoms of prurigo nodularis
1:44pm